Approval · Notice of Compliance 28987 · 2022
HUMIRA: Notice of Compliance 28987
Issued September 16, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28987
- Date
- September 16, 2022
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HUMIRA | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 40 MG per 0.8ML
- ADALIMUMAB 40 MG per 0.4ML
- ADALIMUMAB 100 MG per PEN
- ADALIMUMAB 80 MG per 0.8ML
- ADALIMUMAB 100 MG per SYR
- ADALIMUMAB 10 MG per ML
- ADALIMUMAB 20 MG per 0.2ML